Abstract: Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
April 20, 2021
Assignee:
CORIXA CORPORATION
Inventors:
Robert Hershberg, Nancy Ann Hosken, Michael J. Lodes, Raodoh Mohamath
Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
Abstract: Provided herein relate to modified or mutant forms of cytolysin A (ClyA) and compositions comprising the same. In particular, the modified or mutant forms of ClyA permits efficient capture and/or translocation of a target negative-charged molecule or polymer through the modified or mutant ClyA nanopores at low or physiological ionic strengths. Thus, methods for using the modified or mutant forms of ClyA and compositions, for example, for characterizing a target negatively-charged analyte, e.g., a target polynucleotide, are also provided.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
April 13, 2021
Assignee:
Katholieke Universiteit Leuven
Inventors:
Giovanni Maglia, Lorenzo Franceschini, Tine Brouns, Andrew John Heron, Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace
Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.
Type:
Grant
Filed:
August 9, 2019
Date of Patent:
April 13, 2021
Inventors:
Thomas Hofer, Changhua Ji, Ekkehard Moessner, Pablo Umana
Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
April 6, 2021
Assignee:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
Abstract: The current invention is methods and assays for detecting and/or measuring the modification, i.e., activation or inhibition, of a receptor of interest, without the need to modify the receptor with a label or a tag. The invention uses proteins that move, translocate, are recruited and/or bind to the receptor of interest when the receptor is modified, and proteins in proximity to and/or in the same compartment as the receptor of interest. The proteins are attached or linked to polypeptides that result from the unique cleavage of a modified Oplophorus luciferase. When the proteins are in proximity allowing the unique polypeptides to recombine, a luminescent signal is generated. The invention also includes vector encoding these proteins, cells expressing these proteins, compositions, system and kits.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
March 30, 2021
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Jonathan A Javitch, Maria Hauge Pedersen
Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
Type:
Grant
Filed:
February 3, 2017
Date of Patent:
March 9, 2021
Assignees:
Rigshospitalet, University of Copenhagen
Inventors:
Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
February 23, 2021
Assignee:
FRED HUTCHINSON CANCER RESEARCH CENTER
Inventors:
Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
Type:
Grant
Filed:
September 27, 2017
Date of Patent:
February 2, 2021
Assignee:
EpicentRx, Inc.
Inventors:
Christopher Larson, Tony R. Reid, Bryan T. Oronsky
Abstract: Monoclonal antibody that specifically binds the interleukin 1 receptor type 1 (IL-1RAcP), or an antigen binding fragment thereof, comprising: a) a heavy chain variable region (VH) comprising CDR1H, CDR2H and/or CDR3H, wherein the CDR1H region comprises an amino acid sequence selected from the group of SEQ ID NO: 155-231, wherein the CDR2H region comprises an amino acid sequence selected from the group of SEQ ID NO: 232-308, and wherein the CDR3H region comprises an amino acid sequence selected from the group of SEQ ID NO: 309-385; and b) a light chain variable region (VL) comprising CDR1L, CDR2L and/or CDR3L, wherein the CDR1L region comprises an amino acid sequence selected from the group of SEQ ID NO: 386-462, wherein the CDRL2 region comprises an amino acid sequence selected from the group of SEQ ID NO: 463-539, and wherein the CDR3L region comprises an amino acid sequence selected from the group of SEQ ID NO: 540-616.
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
February 2, 2021
Assignee:
Acceleron Pharma Inc.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne Sako, Robert Scott Pearsall, Roselyne Castonguay
Abstract: Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
Type:
Grant
Filed:
January 30, 2020
Date of Patent:
January 26, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Thomas J. Kipps, George F. Widhopf, II, Bing Cui
Abstract: Resonance energy transfer (RET)- or protein-fragment complement assay (PCA)-based biosensors useful for assessing the activity of G-proteins are described. These biosensors are based on the competition between the G? subunit and a G?? interacting protein (?? IP) for the binding to the G?? dimer. These biosensors comprises (1) a ?? IP and (2) a G? or G? protein; a GPCR; or a plasma membrane targeting domain, fused to suitable RET or PCA tags. Methods using such biosensors for different applications, including the identification of agents that modulates G-protein activity or for the characterization of GPCR signaling/regulation, such as G-protein preferences and activation profiles of GPCRs, are also described.
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
December 29, 2020
Assignee:
UNIVERSITÉ DE MONTRÉAL
Inventors:
Michel Bouvier, Christian Le Gouill, Mireille Hogue, Viktoriya Lukasheva
Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
December 22, 2020
Assignee:
Apogenix AG
Inventors:
Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
Abstract: Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder. The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains an and Fc fragment. The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
Type:
Grant
Filed:
April 19, 2018
Date of Patent:
November 24, 2020
Assignee:
Apogenix AG
Inventors:
Christian Gieffers, Oliver Hill, Meinolf Thiemann, Tim Schnyder
Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
November 10, 2020
Assignees:
Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
Inventors:
Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
Abstract: Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties.
Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
October 13, 2020
Assignees:
Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
Inventors:
Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
Abstract: The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against ?-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against ?-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising ?-adrenergic receptor or an antigenic peptide thereof and the use of ?-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.
Type:
Grant
Filed:
May 24, 2016
Date of Patent:
October 13, 2020
Inventors:
Harald Heidecke, Kai Schulze-Forster, Carmen Scheibenbogen